Peer-reviewed veterinary case report
Treating feline sporotrichosis with itraconazole and potassium iodide
By Reis, Érica G et al.·Published in Medical mycology·2016·Evandro Chagas National Institute of Infectious Diseases (INI)/Oswaldo Cruz Foundation (Fiocruz), Brazil·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Association of itraconazole and potassium iodide in the treatment of feline sporotrichosis: a prospective study.
- Species:
- cat
Plain-English summary
A group of 30 cats diagnosed with sporotrichosis, a fungal infection, were treated with a combination of itraconazole and potassium iodide to see if it would be more effective than itraconazole alone. After about 14 weeks, 96% of the cats showed signs of recovery, although half of them experienced some side effects, which were managed by pausing treatment or using liver-protecting medications. This combination treatment appears to be a promising option for cats suffering from this infection.
People also search for: cat sporotrichosis treatment · itraconazole for cats · potassium iodide side effects in cats
Abstract
Feline sporotrichosis is an endemic disease in Rio de Janeiro, Brazil, where zoonotic transmission of Sporothrix spp. has been reported since 1998. Itraconazole (ITZ) remains the first choice for treating this disease in cats. However, there have been reports of therapeutic failure and a long-term endeavor. Potassium iodide (KI), considered in the past as a drug with variable effectiveness in cats with sporotrichosis, arises as an important option in the treatment of cats from the endemic area of Rio de Janeiro. In order to evaluate the effectiveness of the association of ITZ and KI in naive cats with sporotrichosis, a prospective cohort study was conducted on 30 cats receiving ITZ 100 mg/day and KI 2.5 mg-20 mg/kg/day. Clinical and laboratory adverse effects were assessed once a month according to the standard care protocol. The cure rate was 96.15% within a median of 14 weeks of treatment. Adverse effects were observed in 50% of cats and were managed with a temporary drug suspension and/or a hepatoprotective therapy. The association of ITZ and KI emerges as an effective option for the treatment of feline sporotrichosis.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/27207412/